APO Research
Talk to an analyst

APO RESEARCH · REPORT

Binge Eating Disorder Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Binge Eating Disorder Drug Market Outlook and Growth Opportunities 2026

20 December 2025196 pages

Choose your research edition.

Industry ResearchBinge Eating Disorder Drug Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Binge Eating Disorder Drug Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Binge Eating Disorder Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Binge Eating Disorder Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Binge Eating Disorder Drug Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Binge Eating Disorder Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Binge Eating Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Binge Eating Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Binge Eating Disorder Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Binge Eating Disorder Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Binge Eating Disorder Drug market include Novo Nordisk, Roche, Sunovion Pharmaceuticals, Opiant Pharmaceuticals, Omeros Corp, Heptares and Chronos Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Binge Eating Disorder Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Binge Eating Disorder Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Binge Eating Disorder Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Binge Eating Disorder Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Binge Eating Disorder Drug Segment by Company

Novo Nordisk

Roche

Sunovion Pharmaceuticals

Opiant Pharmaceuticals

Omeros Corp

Heptares

Chronos Therapeutics

Binge Eating Disorder Drug Segment by Type

Anti-obesity Medications

Anticonvulsants

Antidepressants

Binge Eating Disorder Drug Segment by Application

Retail Pharmacies

Online Pharmacies

Hospital Pharmacies

Binge Eating Disorder Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Binge Eating Disorder Drug status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Binge Eating Disorder Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Binge Eating Disorder Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Binge Eating Disorder Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Binge Eating Disorder Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Binge Eating Disorder Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Binge Eating Disorder Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Binge Eating Disorder Drug market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Binge Eating Disorder Drug industry.

Chapter 3: Detailed analysis of Binge Eating Disorder Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Binge Eating Disorder Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Binge Eating Disorder Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Binge Eating Disorder Drug Industry Trends Table 2. Binge Eating Disorder Drug Industry Drivers Table 3. Binge Eating Disorder Drug Industry Opportunities and Challenges Table 4. Binge Eating Disorder Drug Industry Restraints Table 5. Global Binge Eating Disorder Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Binge Eating Disorder Drug Revenue Share by Company (2021-2026) Table 7. Global Binge Eating Disorder Drug Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Binge Eating Disorder Drug Sales Volume Share by Company (2021-2026) Table 9. Global Binge Eating Disorder Drug Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Binge Eating Disorder Drug Company Ranking, (2024-2026) & (USD Million) Table 11. Global Binge Eating Disorder Drug Key Company Manufacturing Base & Headquarters Table 12. Global Binge Eating Disorder Drug Company, Product Type & Application Table 13. Global Binge Eating Disorder Drug Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Binge Eating Disorder Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Anti-obesity Medications Table 18. Significant Companies of Anticonvulsants Table 19. Significant Companies of Antidepressants Table 20. Global Binge Eating Disorder Drug Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Binge Eating Disorder Drug Sales Volume by Type (2021-2026) & (K Units) Table 22. Global Binge Eating Disorder Drug Sales Volume by Type (2027-2032) & (K Units) Table 23. Global Binge Eating Disorder Drug Sales Volume Share by Type (2021-2026) Table 24. Global Binge Eating Disorder Drug Sales Volume Share by Type (2027-2032) Table 25. Global Binge Eating Disorder Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Binge Eating Disorder Drug Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Binge Eating Disorder Drug Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Binge Eating Disorder Drug Sales Value Share by Type (2021-2026) Table 29. Global Binge Eating Disorder Drug Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Retail Pharmacies Table 31. Significant Companies of Online Pharmacies Table 32. Significant Companies of Hospital Pharmacies Table 33. Global Binge Eating Disorder Drug Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Binge Eating Disorder Drug Sales Volume by Application (2021-2026) & (K Units) Table 35. Global Binge Eating Disorder Drug Sales Volume by Application (2027-2032) & (K Units) Table 36. Global Binge Eating Disorder Drug Sales Volume Share by Application (2021-2026) Table 37. Global Binge Eating Disorder Drug Sales Volume Share by Application (2027-2032) Table 38. Global Binge Eating Disorder Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Binge Eating Disorder Drug Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Binge Eating Disorder Drug Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Binge Eating Disorder Drug Sales Value Share by Application (2021-2026) Table 42. Global Binge Eating Disorder Drug Sales Value Share by Application (2027-2032) Table 43. Global Binge Eating Disorder Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Binge Eating Disorder Drug Sales by Region (2021-2026) & (K Units) Table 45. Global Binge Eating Disorder Drug Sales Market Share by Region (2021-2026) Table 46. Global Binge Eating Disorder Drug Sales by Region (2027-2032) & (K Units) Table 47. Global Binge Eating Disorder Drug Sales Market Share by Region (2027-2032) Table 48. Global Binge Eating Disorder Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Binge Eating Disorder Drug Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Binge Eating Disorder Drug Sales Value Share by Region (2021-2026) Table 51. Global Binge Eating Disorder Drug Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Binge Eating Disorder Drug Sales Value Share by Region (2027-2032) Table 53. Global Binge Eating Disorder Drug Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Binge Eating Disorder Drug Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Binge Eating Disorder Drug Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Global Binge Eating Disorder Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Binge Eating Disorder Drug Sales by Country (2021-2026) & (K Units) Table 58. Global Binge Eating Disorder Drug Sales Market Share by Country (2021-2026) Table 59. Global Binge Eating Disorder Drug Sales by Country (2027-2032) & (K Units) Table 60. Global Binge Eating Disorder Drug Sales Market Share by Country (2027-2032) Table 61. Global Binge Eating Disorder Drug Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Binge Eating Disorder Drug Sales Value Market Share by Country (2021-2026) Table 63. Global Binge Eating Disorder Drug Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Binge Eating Disorder Drug Sales Value Market Share by Country (2027-2032) Table 65. Novo Nordisk Company Information Table 66. Novo Nordisk Business Overview Table 67. Novo Nordisk Binge Eating Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Novo Nordisk Binge Eating Disorder Drug Product Portfolio Table 69. Novo Nordisk Recent Development Table 70. Roche Company Information Table 71. Roche Business Overview Table 72. Roche Binge Eating Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. Roche Binge Eating Disorder Drug Product Portfolio Table 74. Roche Recent Development Table 75. Sunovion Pharmaceuticals Company Information Table 76. Sunovion Pharmaceuticals Business Overview Table 77. Sunovion Pharmaceuticals Binge Eating Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Sunovion Pharmaceuticals Binge Eating Disorder Drug Product Portfolio Table 79. Sunovion Pharmaceuticals Recent Development Table 80. Opiant Pharmaceuticals Company Information Table 81. Opiant Pharmaceuticals Business Overview Table 82. Opiant Pharmaceuticals Binge Eating Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Opiant Pharmaceuticals Binge Eating Disorder Drug Product Portfolio Table 84. Opiant Pharmaceuticals Recent Development Table 85. Omeros Corp Company Information Table 86. Omeros Corp Business Overview Table 87. Omeros Corp Binge Eating Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Omeros Corp Binge Eating Disorder Drug Product Portfolio Table 89. Omeros Corp Recent Development Table 90. Heptares Company Information Table 91. Heptares Business Overview Table 92. Heptares Binge Eating Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Heptares Binge Eating Disorder Drug Product Portfolio Table 94. Heptares Recent Development Table 95. Chronos Therapeutics Company Information Table 96. Chronos Therapeutics Business Overview Table 97. Chronos Therapeutics Binge Eating Disorder Drug Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Chronos Therapeutics Binge Eating Disorder Drug Product Portfolio Table 99. Chronos Therapeutics Recent Development Table 100. Key Raw Materials Table 101. Raw Materials Key Suppliers Table 102. Binge Eating Disorder Drug Distributors List Table 103. Binge Eating Disorder Drug Customers List Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Binge Eating Disorder Drug Product Image Figure 2. Global Binge Eating Disorder Drug Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Binge Eating Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 4. Global Binge Eating Disorder Drug Sales (2021-2032) & (K Units) Figure 5. Global Binge Eating Disorder Drug Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Binge Eating Disorder Drug Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Anti-obesity Medications Image Figure 10. Anticonvulsants Image Figure 11. Antidepressants Image Figure 12. Global Binge Eating Disorder Drug Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Binge Eating Disorder Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Binge Eating Disorder Drug Sales Volume Share by Type (2021-2032) Figure 15. Global Binge Eating Disorder Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Binge Eating Disorder Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Binge Eating Disorder Drug Sales Value Share by Type (2021-2032) Figure 18. Retail Pharmacies Image Figure 19. Online Pharmacies Image Figure 20. Hospital Pharmacies Image Figure 21. Global Binge Eating Disorder Drug Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Binge Eating Disorder Drug Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Binge Eating Disorder Drug Sales Volume Share by Application (2021-2032) Figure 24. Global Binge Eating Disorder Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Binge Eating Disorder Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Binge Eating Disorder Drug Sales Value Share by Application (2021-2032) Figure 27. Global Binge Eating Disorder Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 28. Global Binge Eating Disorder Drug Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Binge Eating Disorder Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Binge Eating Disorder Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Binge Eating Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 32. North America Binge Eating Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Binge Eating Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Binge Eating Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Binge Eating Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Binge Eating Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Binge Eating Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 38. South America Binge Eating Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Binge Eating Disorder Drug Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Binge Eating Disorder Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Binge Eating Disorder Drug Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Binge Eating Disorder Drug Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Anti-obesity Medications
  • Anticonvulsants
  • Antidepressants
Applications
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Novo Nordisk
  • Roche
  • Sunovion Pharmaceuticals
  • Opiant Pharmaceuticals
  • Omeros Corp
  • Heptares
  • Chronos Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Binge Eating Disorder Drug Sales Value (2021-2032)
  4. 1.2.2 Global Binge Eating Disorder Drug Sales Volume (2021-2032)
  5. 1.2.3 Global Binge Eating Disorder Drug Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Binge Eating Disorder Drug Market Dynamics
  1. 2.1 Binge Eating Disorder Drug Industry Trends
  2. 2.2 Binge Eating Disorder Drug Industry Drivers
  3. 2.3 Binge Eating Disorder Drug Industry Opportunities and Challenges
  4. 2.4 Binge Eating Disorder Drug Industry Restraints
3 Binge Eating Disorder Drug Market by Company
  1. 3.1 Global Binge Eating Disorder Drug Company Revenue Ranking in 2025
  2. 3.2 Global Binge Eating Disorder Drug Revenue by Company (2021-2026)
  3. 3.3 Global Binge Eating Disorder Drug Sales Volume by Company (2021-2026)
  4. 3.4 Global Binge Eating Disorder Drug Average Price by Company (2021-2026)
  5. 3.5 Global Binge Eating Disorder Drug Company Ranking (2024-2026)
  6. 3.6 Global Binge Eating Disorder Drug Company Manufacturing Base and Headquarters
  7. 3.7 Global Binge Eating Disorder Drug Company Product Type and Application
  8. 3.8 Global Binge Eating Disorder Drug Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Binge Eating Disorder Drug Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Binge Eating Disorder Drug Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Binge Eating Disorder Drug Market by Type
  1. 4.1 Binge Eating Disorder Drug Type Introduction
  2. 4.1.1 Anti-obesity Medications
  3. 4.1.2 Anticonvulsants
  4. 4.1.3 Antidepressants
  5. 4.2 Global Binge Eating Disorder Drug Sales Volume by Type
  6. 4.2.1 Global Binge Eating Disorder Drug Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Binge Eating Disorder Drug Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Binge Eating Disorder Drug Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Binge Eating Disorder Drug Sales Value by Type
  10. 4.3.1 Global Binge Eating Disorder Drug Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Binge Eating Disorder Drug Sales Value by Type (2021-2032)
  12. 4.3.3 Global Binge Eating Disorder Drug Sales Value Share by Type (2021-2032)
5 Binge Eating Disorder Drug Market by Application
  1. 5.1 Binge Eating Disorder Drug Application Introduction
  2. 5.1.1 Retail Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Binge Eating Disorder Drug Sales Volume by Application
  6. 5.2.1 Global Binge Eating Disorder Drug Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Binge Eating Disorder Drug Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Binge Eating Disorder Drug Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Binge Eating Disorder Drug Sales Value by Application
  10. 5.3.1 Global Binge Eating Disorder Drug Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Binge Eating Disorder Drug Sales Value by Application (2021-2032)
  12. 5.3.3 Global Binge Eating Disorder Drug Sales Value Share by Application (2021-2032)
6 Binge Eating Disorder Drug Regional Sales and Value Analysis
  1. 6.1 Global Binge Eating Disorder Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Binge Eating Disorder Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Binge Eating Disorder Drug Sales by Region: 2021-2026
  4. 6.2.2 Global Binge Eating Disorder Drug Sales by Region (2027-2032)
  5. 6.3 Global Binge Eating Disorder Drug Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Binge Eating Disorder Drug Sales Value by Region (2021-2032)
  7. 6.4.1 Global Binge Eating Disorder Drug Sales Value by Region: 2021-2026
  8. 6.4.2 Global Binge Eating Disorder Drug Sales Value by Region (2027-2032)
  9. 6.5 Global Binge Eating Disorder Drug Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Binge Eating Disorder Drug Sales Value (2021-2032)
  12. 6.6.2 North America Binge Eating Disorder Drug Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Binge Eating Disorder Drug Sales Value (2021-2032)
  15. 6.7.2 Europe Binge Eating Disorder Drug Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Binge Eating Disorder Drug Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Binge Eating Disorder Drug Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Binge Eating Disorder Drug Sales Value (2021-2032)
  21. 6.9.2 South America Binge Eating Disorder Drug Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Binge Eating Disorder Drug Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Binge Eating Disorder Drug Sales Value Share by Country, 2025 VS 2032
7 Binge Eating Disorder Drug Country-level Sales and Value Analysis
  1. 7.1 Global Binge Eating Disorder Drug Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Binge Eating Disorder Drug Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Binge Eating Disorder Drug Sales by Country (2021-2032)
  4. 7.3.1 Global Binge Eating Disorder Drug Sales by Country (2021-2026)
  5. 7.3.2 Global Binge Eating Disorder Drug Sales by Country (2027-2032)
  6. 7.4 Global Binge Eating Disorder Drug Sales Value by Country (2021-2032)
  7. 7.4.1 Global Binge Eating Disorder Drug Sales Value by Country (2021-2026)
  8. 7.4.2 Global Binge Eating Disorder Drug Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Binge Eating Disorder Drug Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Binge Eating Disorder Drug Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Binge Eating Disorder Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novo Nordisk
  2. 8.1.1 Novo Nordisk Company Information
  3. 8.1.2 Novo Nordisk Business Overview
  4. 8.1.3 Novo Nordisk Binge Eating Disorder Drug Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novo Nordisk Binge Eating Disorder Drug Product Portfolio
  6. 8.1.5 Novo Nordisk Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Binge Eating Disorder Drug Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Roche Binge Eating Disorder Drug Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 Sunovion Pharmaceuticals
  14. 8.3.1 Sunovion Pharmaceuticals Company Information
  15. 8.3.2 Sunovion Pharmaceuticals Business Overview
  16. 8.3.3 Sunovion Pharmaceuticals Binge Eating Disorder Drug Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sunovion Pharmaceuticals Binge Eating Disorder Drug Product Portfolio
  18. 8.3.5 Sunovion Pharmaceuticals Recent Developments
  19. 8.4 Opiant Pharmaceuticals
  20. 8.4.1 Opiant Pharmaceuticals Company Information
  21. 8.4.2 Opiant Pharmaceuticals Business Overview
  22. 8.4.3 Opiant Pharmaceuticals Binge Eating Disorder Drug Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Opiant Pharmaceuticals Binge Eating Disorder Drug Product Portfolio
  24. 8.4.5 Opiant Pharmaceuticals Recent Developments
  25. 8.5 Omeros Corp
  26. 8.5.1 Omeros Corp Company Information
  27. 8.5.2 Omeros Corp Business Overview
  28. 8.5.3 Omeros Corp Binge Eating Disorder Drug Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Omeros Corp Binge Eating Disorder Drug Product Portfolio
  30. 8.5.5 Omeros Corp Recent Developments
  31. 8.6 Heptares
  32. 8.6.1 Heptares Company Information
  33. 8.6.2 Heptares Business Overview
  34. 8.6.3 Heptares Binge Eating Disorder Drug Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Heptares Binge Eating Disorder Drug Product Portfolio
  36. 8.6.5 Heptares Recent Developments
  37. 8.7 Chronos Therapeutics
  38. 8.7.1 Chronos Therapeutics Company Information
  39. 8.7.2 Chronos Therapeutics Business Overview
  40. 8.7.3 Chronos Therapeutics Binge Eating Disorder Drug Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Chronos Therapeutics Binge Eating Disorder Drug Product Portfolio
  42. 8.7.5 Chronos Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Binge Eating Disorder Drug Value Chain Analysis
  2. 9.1.1 Binge Eating Disorder Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Binge Eating Disorder Drug Sales Mode & Process
  6. 9.2 Binge Eating Disorder Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Binge Eating Disorder Drug Distributors
  9. 9.2.3 Binge Eating Disorder Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst